Linda Stocum, Associate Editor

ICYMI, this week we had stories on Vial's CRO launch, our conference coverage coming up this weekend, and more.

This episode of The Cutaneous Connection podcast, explores hair loss and hair treatment of patients with textured or tightly coiled hair. Candrice Heath, MD, FAAP, FAAD a dermatologist and assistant professor of dermatology at the Lewis Katz School of Medicine at Temple University, explains her experience and highlights how all dermatologists can improve their treatment plans.

Vial launches Vial Dermatology contract research organization (CRO) and highlights how it could improve the speed and quality of clinical trials.

A national survey found that patients are willing to try medical cannabis products as potential treatments of their condition. Additionally, some already use over-the-counter cannabis products.

This week's edition of the Mainstream Patients features stories about at-home microdermabrasion, the science of oily hair, and more.

ICYMI, this week we had stories on the continued issues with iPLEDGE, the new data on spesolimab treatment for GPP, and more.

A survey conducted by Dermatology Times® found that many still cannot access the iPLEDGE system. Now some have created guides to get around the issue.

The Skin of Color Society released an article detailing its 2021 achievements, containing what the society considers its most active and successful year.

The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.

FUE is a type of hair transplant that requires physicians to change tools to accommodate different hair and scalp types. Now, a recent study highlights a single device aiming to treat all types of hair situations.

New research has been published in the New England Journal of Medicine on spesolimab as a treatment for generalized pustular psoriasis.

This week's edition of the Mainstream Patients features stories about rosemary oil for hair, Ava Max dealing with Covid-19 hair loss, and more.

ICYMI, some of this week’s featured content includes an exclusive interview about lasers and acne, and articles on 2021's top 20 stories, the declining preference for telehealth, and more.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of December

Dermatology Times® broke the news that the carcinogen benzene was found in multiple sunscreens, but that wasn’t the only major headline of the year. We revisit the 20 stories of 2021 that made the greatest impact.

With the complication rate of treatment declining and new devices now available, laser- and energy-based light treatment for acne and scarring continues to evolve.

A recent study investigates the probability of BDD in cosmetic dermatology with the help of a new screening tool.

An article in the Journal of Wound Care surveyed participants on awareness, implementation, barriers, and outcomes of wound hygiene.

A study in the Advances in Skin & Wound Care Journal dove into the clinical aspect of aging skin that clinicians should consider when practicing wound care.

Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.

This week's edition of the Mainstream Patients features stories about the best hair removal methods, pH levels in the skin, and more.

ICYMI, some of this week’s featured content includes an exclusive interview about the occupational dermatoses, and articles on 2021's breakthroughs and disappointments, the risk of psoriasis related to BMI and more.

A study in the Journal of Drugs in Dermatology dove into the effect of ceramide-containing products on stratum corneum lipid levels in dry legs.

A study in the International Journal of Cosmetic Science observed the changes in skin based on different moisturizing formulations.

With this expanded indication, apremilast (Otezla; Amgen) is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

Arcutis has announced that the FDA has accepted the New Drug Application for roflumilast cream for adults and adolescent patients with plaque psoriasis.

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

A recent study investigated apremilast use for psoriasis during COVID-19 infection.

This week's edition of the Mainstream Patients features stories about how to identify DMDM for hair loss, PRF Fillers, and more.